Short-Burst Interval Treadmill Training Cerebral Palsy

November 20, 2023 updated by: Kristie Bjornson

Short-Burst Interval Treadmill Training to Improve Community Walking Activity and Mobility in Cerebral Palsy

Ambulatory children with cerebral palsy (CP) walk predominately in low intensity stride rates with little variability, thus limiting their walking activity and ability to participate in daily life. In contrast, typically developing (TD) children engage in short bursts of intense walking activity interspersed with varying intervals of low intensity walking within daily life. In order to optimize motor learning, active participation, task-specific training and multiple repetitions or massed practice is required to learn new motor skills. Short bursts of vigorous intensity locomotor treadmill training (SBLTT) alternating with low/moderate intensity was specifically designed to mimic activity patterns of TD children in a massed practice format. Pilot data suggests that SBLTT is feasible and enhances walking capacity and performance in daily life for children with CP. This project will examine the effect of SBLTT versus an equivalent dosage of traditional locomotor treadmill training (TLTT) on the primary outcomes of walking capacity and performance in children with CP and whether the effects of SBLTT on walking capacity and performance are mediated by improvements in in muscle power generation. The scientific premise is that SBLTT, that approximates the walking intensity patterns of typically developing (TD) children through a home-based massed practice protocol, will be more effective than TLTT in improving walking capacity and performance. We hypothesize that SBLTT strategies for children with CP modeled on walking patterns of TD children, will be positively mediated by muscle power generation and subsequently improve walking capacity and community walking performance and mobility. Specific aims. Aim #1. Determine the immediate and retention effects of short-burst interval LTT (SBLTT) on walking capacity in ambulatory children with CP. Aim #2. Examine the effects of treatment on community-based walking activity performance and mobility. Aim #3. Explore whether the effects of SBLTT on walking capacity and performance are mediated by muscle power generation. The proposed research will be the first step in a continuum of research that is expected to direct locomotor training protocols and rehab strategies across pediatric disabilities and positively effecting the community walking performance and mobility for children with CP.

Study Overview

Detailed Description

In a randomized clinical trial, 72 ambulatory children with spastic CP (6-10 yrs.) will receive either SBLTT or an equivalent dosage of TLTT for 40 sessions, 5x/week for 8 weeks in a massed practice format. The only difference between training protocols will be the variable training (interval fast versus steady state walking speeds). Thus, the key ingredient will be the intensity of the interval training delivered in a serial blocked practice schedule. Outcomes will be collected at baseline, 4 and 8 weeks to assess dosage, and 24 weeks post training for long term retention with the primary endpoint at 8 weeks.

Study Type

Interventional

Enrollment (Estimated)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Louisiana
      • New Orleans, Louisiana, United States, 70112
        • Recruiting
        • Lousianna State University Health Sciences Center New Orleans
        • Contact:
    • Washington

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 years to 8 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Bilateral spastic cerebral palsy
  • Gross Motor Function Classification Levels II & III
  • Ages 6 years to < 11 years

Exclusion Criteria:

  • Orthopedic or neurosurgery < 9 months prior
  • Injection therapy (Botulinum Toxin/Phenol) < 3 months prior

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Short burst Interval Treadmill Training (SBLTT)
SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of SBLTT
SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
Active Comparator: Traditional Locomotor Treadmill Training (TLTT)
TLTT will consist of walking at steady-state speeds. Participant will receive 40 home-based sessions (5x/week for 8 weeks) of TLTT
TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of < 6/10.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking Capacity-Self-selected walking spee
Time Frame: Baseline to 8 weeks
10 Meter Walk Test
Baseline to 8 weeks
Walking Capacity-Fast walking speed
Time Frame: Baseline to 8 weeks
10 Meter Walk Test- fast speed
Baseline to 8 weeks
Walking Capacity-Endurance
Time Frame: Baseline to 8 weeks
One Minute Walk Test
Baseline to 8 weeks
Walking Performance-level
Time Frame: Baseline to 8 weeks
StepWatch (SW) accelerometry - average total steps per day
Baseline to 8 weeks
Walking Performance-Intensity
Time Frame: Baseline to 8 weeks
StepWatch (SW) accelerometry - average daily steps at low, medium and high step rates
Baseline to 8 weeks
Knee extensor muscle power
Time Frame: Baseline to 8 weeks.
Isokinetic Average Power for Knee extensors at 60deg/s as measured by Biodex.
Baseline to 8 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking Mobility -level home versus community
Time Frame: Baseline to 8 weeks
StepWatch (SW) synchronized with Global Positioning System (GPS) - average strides per day in home versus community
Baseline to 8 weeks
Walking Mobility-intensity home versus community
Time Frame: Baseline to 8 weeks
StepWatch (SW) synchronized with Global Positioning System (GPS) - average strides per day low, medium or high stride rate in home versus community
Baseline to 8 weeks
Mobility
Time Frame: Baseline to 8 weeks
Patient-Reported Outcomes Measurement Information System (PROMIS v1.0 Pediatric Profile) Mobility domain score
Baseline to 8 weeks
Family Gait Priorities and Quality of gait
Time Frame: Baseline to 8 weeks
Parent report Gait Outcome Assessment List (GOAL).total score
Baseline to 8 weeks
Knee extensor muscle torque
Time Frame: Baseline to 8 weeks.
Isokinetic Peak Torque for knee extensors at 60 deg/s as measured by Biodex.
Baseline to 8 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kristie F Bjornson, PhD, PT, Seattle Children's Research Institute
  • Principal Investigator: Noelle Moreau, PhD, PT, Lousianna State University in New Orleans

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 27, 2019

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

May 31, 2026

Study Registration Dates

First Submitted

July 17, 2019

First Submitted That Met QC Criteria

July 17, 2019

First Posted (Actual)

July 19, 2019

Study Record Updates

Last Update Posted (Actual)

November 21, 2023

Last Update Submitted That Met QC Criteria

November 20, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy

Clinical Trials on Short Burst Interval Treadmill Training (SBLTT)

Subscribe